Search Results - against

26 Results

Sort By:

Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function

This technology includes a rat monoclonal antibody termed mAb11 was generated against the human alpha-5 integrin subunit and can provide immunological characterizations without disrupting integrin adhesive function. It permits characterization of its localization even if the receptor is bound to its fibronectin ligand. The antibody is commercially available...

Published: 7/25/2024 | Inventor(s): Steven Akiyama, Susan Yamada, Kenneth Yamada

Keywords(s): Against, Alpha-5, ANTIBODY, DISRUPT, DOES, FUNCTION, Human, INTEGRIN, monoclonal, That, WIXXXX, XAXXXX

Category(s): Application > Research Materials, ResearchProducts > Antibodies, TherapeuticArea > Immunology

Novel VAR2CSA Immunogens and Methods of Use Thereof

The invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen...

Published: 7/25/2024 | Inventor(s): Rui Ma, Niraj Tolia

Keywords(s): Against, CANCER, COMPOSITION, COMPRISING, Diagnostics, IMMUNOGENS, Malaria, Matter, Placental, PROTECT, proteins, That, therapeutics, Used

Category(s): Collaboration Sought > Collaboration

Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody

A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

Published: 7/25/2024 | Inventor(s): Ethan Shevach

Keywords(s): AC5XXX, Against, ALPHA, antibodies, ANTIGENS, Cell, Chain, Clone:, H9.2B8, Hamster, Hybridoma, Listed LPM Nguyen-Antczak as of 4/15/2015, Mab, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, Surface, Vitronectin, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials

Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein

Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal...

Published: 7/25/2024 | Inventor(s): Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Yongping Yang, Jiang Zhu, Lawrence Shapiro, William Schief, Rebecca Rudicell, Ivelin Georgiev, Young Do Kwon, Baoshan Zhang, Gwo-yu Chauang, Wei Shi, Gwo-Yu Chuang, John Mascola

Keywords(s): Against, antibodies, Antibodies., ANTIBODY, Antibody-based, B-Cells, Broadly, Chain, Constructs, CREATION, DA4AXX, DB4AXX, DC5AXX, DD2XXX, Epitope-Specific, Expressing, FUNCTION, Further, GENERAL, GLYCOPROTEIN, gp120, HIV, HIV-1, Identity, Immunoadesion, Immunoadhesin, Isolation, Listed LPM Thalhammer-Reyero as of 4/15/2015, MODE, Modifications, monoclonal, Monoco, Neutizing, Neutralization, Neutralizing, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Probes, Single, Specific, VRC03, VRC03Isolation

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Shihui Liu

Keywords(s): Against, Anthrax, CMG2, EFFICACY, FELINE, FELINE Leukemia, Having, IC2-PA, Improved, Leppla, MARKER, SOLID, Specificity, Strong, Targeting, toxin, tumor, Types, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration

Chimeric Antibodies Against Hepatitis B e-Antigen

The invention relates to recombinant chimeric rabbit/human monoclonal antibody fragments (Fabs) against hepatitis B Virus e-antigen (HBeAg), notably Fab me6. Viral hepatitis is the seventh leading cause of death worldwide. Hepatitis B core antigen (HBcAg) forms an icosahedral structure containing the viral genome. Both the HBcAg and the HBeAg of interest...

Published: 7/30/2024 | Inventor(s): Norman Watts, Alasdair Steven, Paul Wingfield

Keywords(s): Against, antibodies, APPLICATIONS, assay, B, CHARACTERIZATION, chimeric, Chimic, DB4XXX, E-antigen, FAB, Hepalitis, Hepatitis, Potential, Rabbit/human, Their, THERAPY, VLXXXX, WJXXXX, XAXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, Application > Therapeutics, TherapeuticArea > Infectious Disease, ResearchProducts > Antibodies

AMA1-RON2 Complex-Based Vaccine Against Malaria

This technology relates to a malaria vaccine composed of a protein complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 (RON2) with an adjuvant. AMA1 is a crucial component of the Plasmodium invasion machinery and is a leading candidate for antimalarial vaccine development. AMA1-based vaccines have shown ability to block red cell invasion...

Published: 7/25/2024 | Inventor(s): Louis Miller, Prakash Srinivasan

Keywords(s): Against, AMAI-RON2, CHALLENGE, COMPLEX, DC2XXX, Lethal, PLASMODIUM, Protection, PROVIDES, VACCINATION

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines

Viral Like Particles Based Chikungunya Vaccines

Chikungunya virus (CHIKV) is mosquito-borne alphavirus endemic in Africa, India, and Southeast Asia. In 2013 CHIKV infection has also emerged in the Caribbean and a pandemic of CHIKV has re-emerged in the Philippines following Typhoon Haiyan. Currently, there is no vaccine available for the prevention of CHIKV infection and no specific therapy exists...

Published: 7/25/2024 | Inventor(s): Wataru Akahata, Srinivas Rao, Gary Nabel

Keywords(s): Against, ALPHA, ALPHAVIRUS, CAPSID, Chikungunya, CHIKV, DC5BXX, Development, DNA vaccine, E1, E1-E2, E2, Envelope, Generation, Method, MODIFICATION, Modifications, PARTICLES, Patent Category - Biotechnology, PLASMID, PREVENTIVE, production, Protein, proteins, Vaccine, VBXXXX, viral, virus, VIRUS-LIKE, VLPs, VLXXXX, XHXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Diagnostics, ResearchProducts > Research Equipment

Multi-Antigenic Peptide(s) Vaccine and Immunogen for Conferring Streptococcus pneumoniae Immunity

Disease caused by Streptococcus pneumoniae (pneumococcus) is an important cause of morbidity and mortality in the United States and developing countries. Pneumococcal disease is prevalent among the very young, the elderly and immunocompromised individuals. This invention is an improved, immunogenic peptide construct consisting of a combination of...

Published: 7/25/2024 | Inventor(s): George Carlone, Jacquelyn Sampson, Scott Johnson, Danny Jue, Edwin Ades

Keywords(s): Against, ANTIGENIC, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DC4XXX, DCXXXX, DXXXXX, Epitope, Immunogenic, MULTIPLE, OID-NCIRD-DBD, Peptides, PNEUMONIA, PNEUMONIAE, Streptococcus, VJXXXX, VPXXXX, WBXXXX, WFXXXX, WIXXXX, WJXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Ophthalmology, Application > Diagnostics, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Consumer Products, Application > Research Materials, TherapeuticArea > Cardiology, Application > Therapeutics, Application > Occupational Safety and Health, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease

Peptide Vaccines Against Group A Streptococci

This invention relates to synthetic immunoreactive peptides, which are portions of the M proteins of the most prevalent Group A Streptococcus (GAS) serotypes in the United States. These peptides may be useful in development of a flexible, multivalent GAS vaccine. They can be recognized by M type-specific antibodies and are capable of eliciting functional...

Published: 7/25/2024 | Inventor(s): George Carlone, Jacquelyn Sampson, Edwin Ades, Bernard Beall

Keywords(s): Against, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DC4XXX, DCXXXX, GROUP, OID-NCIRD-DBD, Peptide, Streptococci, vaccines

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease

1 2 3